HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase II trial with high-dose elliptinium acetate in metastatic renal cell carcinoma.

Abstract
Sixteen patients with adult metastatic renal cell carcinoma were treated with elliptinium acetate, 80 mg/m2.day, for 3 consecutive days every 3 weeks. Among the 14 patients evaluable, no objective effects were observed. The toxicity was mild and no patients experienced intravascular hemolysis.
AuthorsG Piot, J P Droz, C Theodore, M Ghosn, J Rouëssé, J L Amiel
JournalOncology (Oncology) Vol. 45 Issue 5 Pg. 371-2 ( 1988) ISSN: 0030-2414 [Print] Switzerland
PMID3412745 (Publication Type: Journal Article)
Chemical References
  • Alkaloids
  • Antineoplastic Agents
  • Ellipticines
  • elliptinium
Topics
  • Adult
  • Aged
  • Alkaloids (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Renal Cell (drug therapy)
  • Drug Evaluation
  • Ellipticines (therapeutic use)
  • Female
  • Humans
  • Kidney Neoplasms (drug therapy)
  • Male
  • Middle Aged
  • Neoplasm Metastasis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: